Context Therapeutics (CNTX) AI Stock Analysis

• Market Cap: $136.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: N/A
• EPS Growth: 69.30%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 91,879,170
• 10 Day Avg. Volume: 2,204,982
• 30 Day Avg. Volume: 1,197,912
• PEG Ratio: 0.03
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.09
• Enterprise Value/Market Cap: 0.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.79K
• Enterprise Value/Ebitda: -0.53
• 1Y Price Target: $5.25
• Price Target Upside: 250.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $1.50 ▲(0.00% Upside)

The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn). Technicals are supportive with a strong uptrend, though overbought signals add pullback risk. Valuation is constrained by negative earnings, while recent corporate updates modestly improve the outlook through clearer pipeline milestones and reduced listing risk.

Positive Factors

Focused T‑cell engager pipeline

A clear, focused pipeline of three bispecific T‑cell engager programs positions the company in a structural growth area of oncology. Multiple programs diversify clinical risk and, if clinical data are positive, create sustainable strategic optionality for partnerships or approvals.

Cash runway into 2027

Having an explicit cash runway into 2027 provides durable operational visibility, allowing advancement of multiple Phase 1 milestones in 2026 without immediate financing. This reduces near-term financing overhang and supports execution on clinical development plans.

Very low financial leverage

Extremely low debt levels give the company financial flexibility and limit creditor risk, important for a development-stage biotech. This conservatively financed balance sheet supports continued R&D funding options and partnership negotiation leverage.

Negative Factors

Pre-revenue with sustained net losses

The company remains pre-revenue and recorded a sizable TTM net loss, reflecting a cost base unsupported by commercial sales. This structural lack of revenues means long-term viability depends on trial success or continued external funding, raising execution risk.

Negative operating and free cash flow

Persistent negative operating and free cash flow indicate ongoing cash burn typical of early biotech but create a durable financing need. Continued cash outflows pressure resources and magnify the impact of any clinical delays on the company's ability to fund operations without dilution.

Reliance on equity financings (dilution risk)

An expanded equity sales agreement signals structural reliance on capital markets to fund development. For a pre-revenue company, repeated equity raises are likely if milestones slip, creating persistent dilution risk and potential governance/ownership impacts for existing shareholders.

Context Therapeutics Business Overview & Revenue Model

Company Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Context Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company engages in strategic partnerships and collaborations with other pharmaceutical firms to advance its clinical trials and bring its therapies to market. Revenue is generated through milestone payments, licensing agreements, and potential future sales of approved drugs. Additionally, Context Therapeutics may receive funding through government grants and private investments to support its research and development activities.

Context Therapeutics Financial Statement Overview

Summary

Context Therapeutics faces severe financial challenges with no revenue generation and persistent losses. The balance sheet shows some improvement with increased equity, but the company remains reliant on external financing to bridge operational cash deficits. The financial health of the company is concerning given the industry dynamics and lack of profitability.

Income Statement

The income statement reveals significant challenges with no revenue generation and consistently negative net income, EBIT, and EBITDA over the years. The company is struggling with profitability and growth, reflected in the absence of gross profit and net profit margins.

Balance Sheet

The balance sheet shows an improvement in stockholders' equity and a reduction in liabilities over the years. However, the absence of revenue and high levels of net debt in past years highlight potential solvency issues. The debt-to-equity ratio has improved but remains a concern for financial stability.

Cash Flow

The cash flow statement indicates substantial negative free cash flow and operating cash flow, suggesting insufficient cash generation from operations. Although there is a recent influx of financing cash flow, the company heavily depends on external financing, posing risks to cash flow sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-4.07K	0.00	0.00	0.00	0.00	0.00
EBITDA	-29.28M	-29.91M	-25.06M	-14.87M	-10.39M	-2.57M
Net Income	-26.44M	-26.73M	-23.96M	-14.84M	-10.46M	6.64M
Balance Sheet
Total Assets	79.23M	98.13M	16.06M	37.97M	51.31M	467.34K
Cash, Cash Equivalents and Short-Term Investments	76.94M	94.43M	14.45M	35.50M	49.64M	341.04K
Total Debt	140.20K	219.38K	0.00	55.08K	0.00	5.95M
Total Liabilities	6.06M	2.86M	4.19M	3.21M	3.03M	17.39M
Stockholders Equity	73.17M	95.27M	11.87M	34.76M	48.27M	-16.92M
Cash Flow
Free Cash Flow	-22.38M	-29.31M	-21.05M	-14.09M	-9.05M	-1.03M
Operating Cash Flow	-22.35M	-14.56M	-21.05M	-13.55M	-8.80M	-1.03M
Investing Cash Flow	-33.95K	-14.76M	0.00	-536.84K	-250.00K	0.00
Financing Cash Flow	14.52M	109.29M	0.00	-102.07K	58.39M	1.15M

Context Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Positive. The current price of 1.5 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.20, and above the 200-day MA of 0.93, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 61.01 is Neutral, neither overbought nor oversold. The STOCH value of 42.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTX.

Context Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNTX	56 Neutral	$136.90M	-5.36	-33.68%	―	―	69.30%
WHWK	56 Neutral	$121.12M	20.25	-13.82%	―	-42.62%	―
ADAG	52 Neutral	$74.94M	-2.64	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QNCX	47 Neutral	$164.26M	-2.47	-247.78%	―	―	2.26%
ANEB	44 Neutral	$46.43M	-4.72	-145.11%	―	―	23.10%

Context Therapeutics Corporate Events

Context Therapeutics Highlights T Cell Engager Pipeline Strategy

On January 8, 2026, Context Therapeutics updated its corporate presentation to outline its strategy of building a leading pipeline of T cell engager therapies for solid tumors, highlighting three main bispecific antibody programs—CTIM-76 (Claudin 6 x CD3), CT-95 (mesothelin x CD3), and CT-202 (Nectin-4 x CD3)—each designed for highly selective tumor targeting and reduced cytokine release risk in large oncology indications. The company reported a strong financial position with an expected cash runway into 2027 and detailed upcoming development milestones, including updated Phase 1a data and dose selection for CTIM-76 in the second quarter of 2026, initial Phase 1a data for CT-95 in mid-2026, and regulatory filings to begin first-in-human trials for CT-202 in the second quarter of 2026, positioning Context to compete in a growing TCE market that has already seen multiple successful commercial launches in both solid and liquid tumors.

The most recent analyst rating on (CNTX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.

Context Therapeutics Reports Q3 2025 Financial Results

On November 5, 2025, Context Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical trials. The company is progressing with its CTIM-76 and CT-95 trials, showing promising safety profiles and preliminary anti-tumor activity in early phases. The company plans to continue dose escalation and expects to release further data in 2026, which could impact its market positioning and stakeholder interests.

The most recent analyst rating on (CNTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.

Context Therapeutics Amends Sales Agreement with Leerink

Context Therapeutics Inc. has amended its Sales Agreement with Leerink Partners LLC to increase the aggregate offering amount of its common stock shares to $75 million, excluding shares previously sold. As of October 24, 2025, the company had sold shares worth approximately $15 million under a prior prospectus. The amendment allows for further sales under a new registration statement, with proceeds intended for research, development, and general corporate purposes. The agreement includes customary terms and allows termination by either party with notice.

The most recent analyst rating on (CNTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.

Context Therapeutics Regains Nasdaq Compliance

Context Therapeutics Inc. received a notification from Nasdaq on February 27, 2025, regarding non-compliance with the Minimum Bid Price Rule, as its stock price fell below $1.00 for 30 consecutive business days. Initially given until August 26, 2025, to regain compliance, the company was later granted an extension until February 23, 2026. By October 17, 2025, Context Therapeutics successfully met the requirement, maintaining a stock price of $1.00 or greater for 10 consecutive days, and Nasdaq has closed the matter.

The most recent analyst rating on (CNTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.